alloSHRINK - Standard cHemotherapy Regimen and Immunotherapy With Allogeneic NKG2D-based CYAD-101 Chimeric Antigen Receptor T-cells

Name: alloSHRINK - Standard cHemotherapy Regimen and Immunotherapy With Allogeneic NKG2D-based CYAD-101 Chimeric Antigen Receptor T-cells
License: Public Domain

Celyad Oncology SA

ClinicalTrials.gov · Datasets · License: Public Domain

Open Source ↗

unresectable metastatic colorectal cancer

This document is indexed with metadata only — full text is not available in the archive for this record. Open the official source ↗

Record · ID 383553
Retrieved via Conceptio — every document is proof-bundled with source, license, and retrieval metadata.